Updated results on AVO therapeutic triplet regimen in untreated patients with CLL
In this MEDtalk, MD Christine Ryan presents updated results from a multicenter phase 2 study investigating the effects of acalabrutinib, venetoclax, and obinutuzumab (AVO) combination in patients with previously untreated CLL. The study suggests AVO as a highly active triplet combination for this group of patients, also the once enriched for high-risk disease. AVO is currently undergoing investigation in a phase 3 study as well.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.